2월 20일 09:57

Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis

Takeda (TSE:4502/NYSE:TAK ) today announced positive data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO® (vedolizumab) ca ...

임상시험제약연구개발

2월 10일 17:30

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1

Takeda (TSE:4502/NYSE:TAK ) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted P ...

제약인증

1월 29일 15:52

Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead

Takeda (TOKYO:4502/NYSE:TAK ) today announced earnings results for the third quarter of fiscal year 2025 (nine months ended December 31, 2025). Th ...

제약실적

1월 6일 09:04

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)

Takeda (TSE:4502/NYSE:TAK ) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) t ...

제약인증

2025년 12월 18일 17:09

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

Takeda (TSE:4502/NYSE:TAK ) today announced positive topline results for the two pivotal Phase 3 randomized, multicenter, double-blind, placebo- a ...

임상시험제약연구개발

2025년 12월 7일 16:00

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX ) and Takeda (TSE:4502/NYSE:TAK ) announce that new 52-week results from the pivotal Phase 3 VERIFY study ...

제약연구개발

2025년 11월 9일 09:50

Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy

Takeda (TSE:4502/NYSE:TAK ) today announced new interim data from the Phase 1b, open-label, proof-of-concept study of subcutaneous mezagitamab (TA ...

임상시험제약연구개발

2025년 11월 4일 08:39

New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization

Takeda (TSE:4502/NYSE:TAK ) announced the completion of the 7-year pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) ...

임상시험제약연구개발

2025년 10월 30일 16:51

Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filings This Fiscal Year

Takeda (TOKYO:4502/NYSE:TAK ) today announced earnings results for the first half of fiscal year 2025 (six months ended Sep 30, 2025) and updated ...

제약실적

2025년 10월 22일 14:50

Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors

Takeda (TSE:4502/NYSE:TAK ) today announced that it has entered into a license and collaboration agreement with Innovent Biologics (HKEX: 01801) f ...

제약종양제휴

2025년 9월 24일 09:32

20,000 + Takeda Employees Voted to Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems in 94 Countries

Takeda (TOKYO:4502/NYSE: TAK) today committed JPY 4.6 billion (approx. USD 32.1 million) to four new Global Corporate Social Responsibility (CSR) ...

제약환경 사회 지배구조사업 확장

2025년 9월 17일 08:59

Takeda and VELA to Ship Medicines Across the Atlantic Using First-of-its-Kind Wind-Powered Trimaran

Takeda (TSE:4502/NYSE:TAK) and VELA Transport today announced their business partnership, with Takeda set to become the first biopharmaceutical co ...

제약물류제휴

2025년 9월 8일 17:39

Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025

Takeda (TSE:4502/NYSE:TAK ) will present data from two global Phase 3 double-blind, placebo-controlled studies of oveporexton (TAK-861)[1], a pote ...

제약연구개발

2025년 9월 7일 16:11

U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease

Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Applic ...

제약연구개발

2025년 7월 30일 16:11

Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression

Takeda (TOKYO:4502/NYSE:TAK ) today announced earnings results for the first quarter of fiscal year 2025 (three months ended June 30, 2025), with ...

제약실적

2025년 7월 23일 14:30

Takeda Receives FDA 510(k) Clearance for HyHub™ and HyHub™ Duo Devices to Simplify HYQVIA® Administration

Takeda (TSE:4502/NYSE:TAK ) today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for HyHub™ and HyHub™ Du ...

제약인증

2025년 7월 23일 14:30

다케다, HyHub™ 및 HyHub™ Duo 장치에 대한 FDA 510 승인 획득해 하이큐비아® 투여 간소화

다케다(TSE:4502/NYSE:TAK )가 오늘 미국 식품의약국(Food and Drug Administration, FDA)이 17세 이상 환자용 장치인 HyHub™ 및 HyHub™ Duo에 대해 510(k) 승인을 부여했다고 발 ...

제약인증

2025년 7월 14일 16:29

Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1

Takeda (TSE:4502/NYSE:TAK ) today announced that all primary and secondary endpoints were met in two Phase 3 randomized, double-blind, placebo-con ...

임상시험제약연구개발

2025년 7월 1일 14:10

Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content

Takeda (TSE:4502/NYSE:TAK ) today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID ERC [immune globulin in ...

제약인증

2025년 6월 25일 16:20

Takeda Announces New Assignments of Directors

Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting, following the 149th Annual ...

의료 기술제약인사

2025년 6월 4일 11:40

European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD

Takeda (TSE:4502/NYSE:TAK ) today announced that the European Commission (EC) approved ADCETRIS® (brentuximab vedotin) in combination with etoposi ...

임상시험제약인증

2025년 6월 2일 11:25

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX ) and Takeda (TSE:4502/NYSE:TAK ) announced detailed results from the Phase 3, randomi ...

임상시험제약연구개발

2025년 5월 28일 08:44

Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award

Takeda (TSE:4502/NYSE:TAK ) today announced that applications are now open for its Innovators in Science Award. This prestigious global award, ori ...

제약과학공모

2025년 5월 18일 12:55

The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1

Takeda (TSE: 4502/NYSE:TAK ) today announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-8 ...

임상시험제약연구개발

2025년 5월 18일 12:55

뉴잉글랜드 의학저널, 1형 기면증 환자 대상 경구용 오렉신 수용체 2 작용제 오베포렉스턴(TAK-861) 2b상 임상시험 데이터 발표

다케다(Takeda)(도쿄증권거래소: 4502/뉴욕증권거래소: TAK )는 오늘, 뉴잉글랜드 의학저널(New England Journal of Medicine) 이 1형 기면증(NT1) 환자 대상 오베포렉스턴(TAK-8 ...

임상시험제약연구개발

 전체 기업